Literature DB >> 30086458

Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells.

Jinjing Cun1, Qifeng Yang2.   

Abstract

The abnormal expression of miR-92a-3p was detected in multiple cancers. However, the biological role and underlying mechanism of miR-92a-3p in tamoxifen-resistant cells are still unknown. The main objective of our study was to find potential miR-92a-3p regulating pathways involved in tamoxifen resistance and to construct their regulatory network using bioinformatics. Four gene expression profiles were retrieved from GEO database and the GEO2R tool was used for analysis. GSE41922 and GSE42072 were applied to investigate aberrant miR-92a-3p expression in breast cancer serum and tissue. We found that miR-92a-3p expression was higher in breast cancer serum or tissue than in healthy volunteer serum or adjacent normal tissue, and high expression of miR-92a-3p could predict poor prognosis of breast cancer patients. In our qRT-PCR validation, we found that miR-92a-3p was upregulated in tamoxifen-resistant cells. MiR-92a-3p might play a role in tamoxifen resistance. In order to find the relationship between miR-92a-3p and some key genes and their potential molecular mechanisms in tamoxifen-resistant cells. The microarray data GSE26459 and GSE28267 were analyzed to determine the differentially expressed genes (DEGs) or miRNAs (DEMs). Furthermore, the related long non-coding RNAs (lncRNAs) were screened with starBase v2.0. Finally,microRNA.org,miRDB, targetminer and targetscan were applied to predict the targets of miR-92a-3p. Through analysis, we find that miR-92a-3p may be used as a potential biomarker for early detection of cancer and monitoring the efficacy of endocrine therapy.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bioinformatics analysis; Breast cancer; Gene Expression Omnibus database; MYC; MiR-92a-3p; Tamoxifen resistance

Mesh:

Substances:

Year:  2018        PMID: 30086458     DOI: 10.1016/j.biopha.2018.07.158

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

1.  Circ_0002232 Acts as a Potential Biomarker for AML and Reveals a Potential ceRNA Network of Circ_0002232/miR-92a-3p/PTEN.

Authors:  Xiao-Yu Su; Qian Zhao; Jin-Ming Ke; De-Hong Wu; Xin Zhu; Jiang Lin; Zhao-Qun Deng
Journal:  Cancer Manag Res       Date:  2020-11-19       Impact factor: 3.989

2.  LncRNA TBX5-AS1 Regulates the Tumor Progression Through the PI3K/AKT Pathway in Non-Small Cell Lung Cancer.

Authors:  Qing-Hai Qu; Shui-Zheng Jiang; Xin-Ying Li
Journal:  Onco Targets Ther       Date:  2020-08-12       Impact factor: 4.147

3.  The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway.

Authors:  Zhiyu Wang; Liang Liu; Yuankun Du; Yuan Mi; Lei Wang
Journal:  Cell Biol Toxicol       Date:  2021-03-23       Impact factor: 6.691

4.  Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures.

Authors:  Aline Do Minh; Alexandra T Star; Jacek Stupak; Kelly M Fulton; Arsalan S Haqqani; Jean-François Gélinas; Jianjun Li; Susan M Twine; Amine A Kamen
Journal:  Viruses       Date:  2021-04-29       Impact factor: 5.048

5.  Investigation of MiR-92a as a Prognostic Indicator in Cancer Patients: a Meta-Analysis.

Authors:  Yizhong Peng; Donghua Huang; Xiangcheng Qing; Lu Tang; Zengwu Shao
Journal:  J Cancer       Date:  2019-07-23       Impact factor: 4.207

6.  CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.

Authors:  J L Hu; W Wang; X L Lan; Z C Zeng; Y S Liang; Y R Yan; F Y Song; F F Wang; X H Zhu; W J Liao; W T Liao; Y Q Ding; L Liang
Journal:  Mol Cancer       Date:  2019-05-07       Impact factor: 27.401

7.  ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network.

Authors:  Haixiu Yang; Yanjun Xu; Desi Shang; Hongbo Shi; Chunlong Zhang; Qun Dong; Yizheng Zhang; Ziyi Bai; Shujun Cheng; Xia Li
Journal:  Ann Transl Med       Date:  2020-11

Review 8.  miRNA-based biomarkers, therapies, and resistance in Cancer.

Authors:  Boxue He; Zhenyu Zhao; Qidong Cai; Yuqian Zhang; Pengfei Zhang; Shuai Shi; Hui Xie; Xiong Peng; Wei Yin; Yongguang Tao; Xiang Wang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

Review 9.  miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.

Authors:  Erik Kudela; Marek Samec; Lenka Koklesova; Alena Liskova; Peter Kubatka; Erik Kozubik; Tomas Rokos; Terezia Pribulova; Eva Gabonova; Marek Smolar; Kamil Biringer
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

10.  Analysis of exosome-derived microRNAs reveals insights of intercellular communication during invasion of breast, prostate and glioblastoma cancer cells.

Authors:  Francesca Lessi; Paolo Aretini; Milena Rizzo; Mariangela Morelli; Michele Menicagli; Sara Franceschi; Chiara Maria Mazzanti
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.